The FDA's FastTrack program is designed to facilitate the development and expedite the review of investigational drugs that demonstrate the potential to address unmet medical needs in serious or life-threatening conditions.
Artios receives FDAFastTrack designation for DNA polymerase theta (Polθ) inhibitor ART6043 for treatment of gBRCA-mutated HER2-negative breast cancer ... .
... next-level therapies for inflammatory diseases, today announces that the FDA has granted FastTrack designation for sonelokimab for the treatment of moderate‑to‑severe PPP.
FastTrack Designation is an FDA program designed to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening condition or address unmet medical needs to facilitate the development of drugs.
The FDAFastTrack process is designed to facilitate the development and expedite the review of new drugs and vaccines that are intended to treat or prevent serious conditions and have the potential to address an unmet medical need.